COMPASS Pathways (NasdaqGS:CMPS) just announced a collaboration with the U.S. Department of Veterans Affairs on the PIVOT ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 ...

COMPASS Pathways leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission. Read why CMPS ...

Key Points Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better. Compass Pathways remains on ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results ...

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. COMPASS Pathways plc (NASDAQ:CMPS) is one of the best psychedelic stocks on our list. TheFly reported on July ...

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Some of the most important upcoming catalysts for Compass' stock have little to do with its own research and development (R&D) or business development activities. Lykos Therapeutics, a psychedelic ...

While about 100 clinical trials focused on psychedelic compounds are chugging along in the regulatory pathway to examine the potential the drugs have to treat illnesses like depression and alcoholism, ...